CompletedPhase 1NCT02705638
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Studying Autoimmune pancreatitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Mark D Topazian, MDMayo Clinic
- Intervention
- Rituximab(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2019
Study locations (1)
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Collaborators
Celgene Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02705638 on ClinicalTrials.govOther trials for Autoimmune pancreatitis
Additional recruiting or active studies for the same condition.